Next Article in Journal
Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials
Next Article in Special Issue
Liver Kinase B1—A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women
Previous Article in Journal
Involvement of N-glycan in Multiple Receptor Tyrosine Kinases Targeted by Ling-Zhi-8 for Suppressing HCC413 Tumor Progression
cancers-logo
Article Menu

Article Menu

Printed Edition

A printed edition of this Special Issue is available at MDPI Books....
Open AccessArticle

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

1
Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen–Nuremberg, Universitätsstrasse 21–23, 91054 Erlangen, Germany
2
Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany
3
Department of Gynecology and Obstetrics, Ulm University Hospital, 89070 Ulm, Germany
4
Oncologianova GmbH, 45657 Recklinghausen, Germany
5
Marienhospital Bottrop, 46236 Bottrop, Germany
6
Department of Bone Oncology, Nordwest Hospital, 60488 Frankfurt, Germany
7
Oncology Practice at Bethanien Hospital Frankfurt; 60389 Frankfurt, Germany
8
Department of Gynecology and Obstetrics, Biostatistics Unit, Erlangen University Hospital, 91054 Erlangen, Germany
9
Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
10
Charité University Hospital, Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, 12203 Berlin, Germany
11
Department of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany
12
Department of Gynecology, Hamburg-Eppendorf University Medical Center, 20246 Hamburg, Germany
13
ClinSol GmbH & Co KG, 97074 Würzburg, Germany
14
Department of Gynecology and Obstetrics, Dresden University Hospital, 01307 Dresden, Germany
15
gSUND Gynäkologie Kompetenzzentrum Stralsund, 18435 Stralsund, Germany
16
Gynäkologische Praxisklinik am Rosengarten, 68165 Mannheim, Germany
17
Medizinischen Versorgungszentrum Onkologie, Onkologie im Elisenhof, 80335 Munich, Germany
18
Department of Gynecology and Obstetrics, Medizinisches Zentrum Bonn Friedensplatz, 53111 Bonn, Germany
19
Department of Gynecology and Obstetrics, Breast Center and Comprehensive Cancer Center Munich, Munich University Hospital, 80337 Munich, Germany
20
Department of Gynecology, Martin Luther University of Halle-Wittenberg, 06120 Halle (Saale), Germany
21
Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, 13125 Berlin, Germany
22
Department of Gynecology and Obstetrics, Düsseldorf University Hospital, 40225 Düsseldorf, Germany
23
National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Heidelberg University Hospital, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(1), 10; https://doi.org/10.3390/cancers11010010
Received: 28 October 2018 / Revised: 16 December 2018 / Accepted: 19 December 2018 / Published: 21 December 2018
(This article belongs to the Special Issue Treatment Strategies and Survival Outcomes in Breast Cancer)
This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH, 85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH → T-DM1 was administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative hormone receptor status, and visceral or brain metastases were associated with more frequent use of this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients. As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of this sequence is similar to that in the approval study. View Full-Text
Keywords: advanced breast cancer; metastatic; chemotherapy; antihormone therapy; HER2 c-erbB2; HER2/neu; trastuzumab; pertuzumab; T-DM1; lapatinib advanced breast cancer; metastatic; chemotherapy; antihormone therapy; HER2 c-erbB2; HER2/neu; trastuzumab; pertuzumab; T-DM1; lapatinib
Show Figures

Figure 1

MDPI and ACS Style

Lux, M.P.; Nabieva, N.; Hartkopf, A.D.; Huober, J.; Volz, B.; Taran, F.-A.; Overkamp, F.; Kolberg, H.-C.; Hadji, P.; Tesch, H.; Häberle, L.; Ettl, J.; Lüftner, D.; Wallwiener, M.; Müller, V.; Beckmann, M.W.; Belleville, E.; Wimberger, P.; Hielscher, C.; Geberth, M.; Abenhardt, W.; Kurbacher, C.; Wuerstlein, R.; Thomssen, C.; Untch, M.; Fasching, P.A.; Janni, W.; Fehm, T.N.; Wallwiener, D.; Schneeweiss, A.; Brucker, S.Y. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers 2019, 11, 10. https://doi.org/10.3390/cancers11010010

AMA Style

Lux MP, Nabieva N, Hartkopf AD, Huober J, Volz B, Taran F-A, Overkamp F, Kolberg H-C, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Schneeweiss A, Brucker SY. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers. 2019; 11(1):10. https://doi.org/10.3390/cancers11010010

Chicago/Turabian Style

Lux, Michael P.; Nabieva, Naiba; Hartkopf, Andreas D.; Huober, Jens; Volz, Bernhard; Taran, Florin-Andrei; Overkamp, Friedrich; Kolberg, Hans-Christian; Hadji, Peyman; Tesch, Hans; Häberle, Lothar; Ettl, Johannes; Lüftner, Diana; Wallwiener, Markus; Müller, Volkmar; Beckmann, Matthias W.; Belleville, Erik; Wimberger, Pauline; Hielscher, Carsten; Geberth, Matthias; Abenhardt, Wolfgang; Kurbacher, Christian; Wuerstlein, Rachel; Thomssen, Christoph; Untch, Michael; Fasching, Peter A.; Janni, Wolfgang; Fehm, Tanja N.; Wallwiener, Diethelm; Schneeweiss, Andreas; Brucker, Sara Y. 2019. "Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry" Cancers 11, no. 1: 10. https://doi.org/10.3390/cancers11010010

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop